Literature DB >> 15517647

Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis.

Carol A Wallace1, Nicolino Ruperto, Edward Giannini.   

Abstract

OBJECTIVE: To develop preliminary criteria for inactive disease and clinical remission for select categories of juvenile idiopathic arthritis (JIA), and to decide what such clinical states should predict in terms of probability of disease recurrence.
METHODS: A Delphi serial questionnaire consensus-formation approach was used initially to gather criteria in use by pediatric rheumatologists (PR) for defining clinical remission in oligoarticular (persistent and extended), rheumatoid factor (RF) positive and negative polyarticular, and systemic JIA. Results from sequential questionnaires provided an agenda for a nominal group technique (NGT) conference to reach consensus on unresolved questions.
RESULTS: One hundred and thirty PR from 34 countries responded to the questionnaires and 20 PR from 9 countries attended the conference. Draft criteria for inactive disease include the following: no active arthritis; no fever, rash, serositis, splenomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis; normal erythrocyte sedimentation rate or C-reactive protein; and a physician's global assessment of disease activity rated at the best score possible for the instrument used. According to consensus vote, 6 continuous months of inactive disease on medication defines clinical remission on medication, while 12 months of inactive disease off all anti-arthritis (and anti-uveitis) medications defines clinical remission off medication. The finalized criteria for remission off medication ideally should predict that a patient has </= 20% probability of disease recurrence within the next 5 years.
CONCLUSION: Using consensus formation techniques, we formulated preliminary criteria for inactive disease and clinical remission on and off medication for use in select categories of JIA. Retrospective validation is in progress; prospective validation will follow. Future efforts will include other categories of JIA.

Entities:  

Mesh:

Year:  2004        PMID: 15517647

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  200 in total

1.  Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus.

Authors:  Rina Mina; Emily von Scheven; Stacy P Ardoin; B Anne Eberhard; Marilynn Punaro; Norman Ilowite; Joyce Hsu; Marisa Klein-Gitelman; L Nandini Moorthy; Eyal Muscal; Suhas M Radhakrishna; Linda Wagner-Weiner; Matthew Adams; Peter Blier; Lenore Buckley; Elizabeth Chalom; Gaëlle Chédeville; Andrew Eichenfield; Natalya Fish; Michael Henrickson; Aimee O Hersh; Roger Hollister; Olcay Jones; Lawrence Jung; Deborah Levy; Jorge Lopez-Benitez; Deborah McCurdy; Paivi M Miettunen; Ana I Quintero-del Rio; Deborah Rothman; Ornella Rullo; Natasha Ruth; Laura E Schanberg; Earl Silverman; Nora G Singer; Jennifer Soep; Reema Syed; Larry B Vogler; Ali Yalcindag; Cagri Yildirim-Toruner; Carol A Wallace; Hermine I Brunner
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-03       Impact factor: 4.794

Review 2.  Defining juvenile idiopathic arthritis remission and optimum time for disease-modifying anti-rheumatic drug withdrawal: why we need a consensus.

Authors:  Thomas Broughton; Kate Armon
Journal:  Paediatr Drugs       Date:  2012-02-01       Impact factor: 3.022

Review 3.  Update on the medical treatment of juvenile idiopathic arthritis.

Authors:  Philip J Hashkes; Ronald M Laxer
Journal:  Curr Rheumatol Rep       Date:  2006-12       Impact factor: 4.592

Review 4.  Osteoporosis in juvenile idiopathic arthritis--a practical approach to diagnosis and therapy.

Authors:  Johannes Roth; Susanne Bechtold; Gudrun Borte; Frank Dressler; Hermann J Girschick; Michael Borte
Journal:  Eur J Pediatr       Date:  2007-04-14       Impact factor: 3.183

5.  Infliximab therapy and outcomes in patients with polyarticular juvenile idiopathic arthritis: a single-center study in China.

Authors:  Da-Wei Liu; Jiao-Jiao Chen; Xue-Mei Tang; Yu Zhang; Juan Zhou
Journal:  World J Pediatr       Date:  2019-10-14       Impact factor: 2.764

Review 6.  Network in pediatric rheumatology: the example of the Pediatric Rheumatology International Trials Organization.

Authors:  Nicolino Ruperto; Alberto Martini
Journal:  World J Pediatr       Date:  2008-08       Impact factor: 2.764

Review 7.  Consensus procedures and their role in pediatric rheumatology.

Authors:  Nicolino Ruperto; Silvia Meiorin; Silvia Mirela Iusan; Angelo Ravelli; Angela Pistorio; Alberto Martini
Journal:  Curr Rheumatol Rep       Date:  2008-04       Impact factor: 4.592

8.  Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).

Authors:  Peter A Nigrovic; Timothy Beukelman; George Tomlinson; Brian M Feldman; Laura E Schanberg; Yukiko Kimura
Journal:  Clin Trials       Date:  2018-03-15       Impact factor: 2.486

9.  [Biologics register JuMBO. Long-term safety of biologic therapy of juvenile idiopathic arthritis].

Authors:  K Minden; J Klotsche; M Niewerth; G Horneff; A Zink
Journal:  Z Rheumatol       Date:  2013-05       Impact factor: 1.372

10.  Physical activity, functional ability, and disease activity in children and adolescents with juvenile idiopathic arthritis.

Authors:  S Gueddari; B Amine; S Rostom; D Badri; N Mawani; M Ezzahri; F Moussa; S Shyen; R Abouqal; B Chkirat; N Hajjaj-Hassouni
Journal:  Clin Rheumatol       Date:  2014-03-22       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.